Generate Biomedicines (NASDAQ:GENB - Get Free Report) had its price objective decreased by analysts at Morgan Stanley from $22.00 to $21.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has an "overweight" rating on the stock. Morgan Stanley's price target points to a potential upside of 103.69% from the company's previous close.
A number of other equities analysts have also recently commented on the stock. Wall Street Zen cut shares of Generate Biomedicines from a "hold" rating to a "sell" rating in a research report on Saturday, October 17th. Weiss Ratings lowered shares of Generate Biomedicines from a "sell (d+)" rating to a "sell (d)" rating in a research report on Monday. Finally, HC Wainwright restated a "buy" rating on shares of Generate Biomedicines in a research note on Friday, October 30th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $26.20.
Check Out Our Latest Report on GENB
Generate Biomedicines Stock Performance
Shares of NASDAQ GENB traded up $0.47 during midday trading on Wednesday, hitting $10.31. 315,503 shares of the company's stock were exchanged, compared to its average volume of 864,124. The company has a quick ratio of 5.01, a current ratio of 5.01 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.33 billion and a PE ratio of -6.45. Generate Biomedicines has a 12 month low of $9.68 and a 12 month high of $22.67. The company's 50 day moving average price is $14.11 and its 200 day moving average price is $14.07.
Generate Biomedicines (NASDAQ:GENB - Get Free Report) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.18). Generate Biomedicines had a negative net margin of 1,289.97% and a negative return on equity of 151.21%. The business had revenue of $4.22 million during the quarter. As a group, analysts predict that Generate Biomedicines will post -2.46 earnings per share for the current fiscal year.
Institutional Trading of Generate Biomedicines
Several hedge funds have recently added to or reduced their stakes in the company. New York State Common Retirement Fund bought a new stake in Generate Biomedicines in the 3rd quarter valued at $129,000. Susquehanna International Group LLP bought a new position in Generate Biomedicines during the 2nd quarter worth $196,000. AXQ Capital LP acquired a new stake in shares of Generate Biomedicines during the second quarter worth $218,000. Summa Corp. acquired a new stake in shares of Generate Biomedicines during the third quarter worth $250,000. Finally, Magnus Financial Group LLC lifted its holdings in shares of Generate Biomedicines by 39.4% during the third quarter. Magnus Financial Group LLC now owns 21,750 shares of the company's stock worth $327,000 after buying an additional 6,150 shares in the last quarter.
About Generate Biomedicines
(
Get Free Report)
Generate Biomedicines is a biotechnology company that uses generative artificial intelligence and experimental biology to design and develop medicines. Founded in 2018 by Flagship Pioneering, the company is based in Somerville, Massachusetts. Its platform is designed to create new proteins with potential therapeutic applications, including antibodies and other biologic medicines. Generate is advancing a drug-development pipeline across areas such as immunology and oncology; one of its candidates, GB-0895, is being developed for asthma.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Generate Biomedicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Generate Biomedicines wasn't on the list.
While Generate Biomedicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.